Intelligent Bio Solutions Inc. (INBS)
After hours:
| Previous Close | 1.9500 |
| Open | 1.9500 |
| Bid | 1.8700 x 100 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.8100 - 1.9700 |
| 52 Week Range | 1.8100 - 44.8800 |
| Volume | |
| Avg. Volume | 66,334 |
| Market Cap | 5.798M |
| Beta (5Y Monthly) | 4.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -29.5600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.00 |
GlobeNewswireIntelligent Bio Solutions to Participate in the Sidoti Small-Cap Conference on June 12-13, 2024
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Sidoti Small-Cap Conference being held virtually June 12-13, 2024. Presentation DetailsDate: Wednesday, June 12, 2024Time: 4:00 p.m. Eastern TimeRegistration/Webcast Link: https://sidoti.zoom.us/webinar/register/WN_BB5QumW3TK2
- GlobeNewswire
Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful recruitment and commencement of screening for subjects in its pharmacokinetic (PK) study, a critical component of the Company's FDA 510(k) regulatory pathway for clearance. Harry Simeonidis, President and CEO at INBS, commented, "As we navigate the FDA 510(k) r
- GlobeNewswire
Intelligent Bio Solutions Unveils Key Performance Indicator Growth in the United Kingdom as Drug Screening Industry Combats Drug Test Cheating and Searches for Simpler, Faster, Non-Invasive and More Cost-Effective Solutions
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today unveiled key performance indicators from its United Kingdom operations. These indicators have contributed to the Company’s growth as the drug screening industry continues to combat drug test cheating and searches for simpler, faster, non-invasive, and more cost-effective solutions. For
